COVID-19 vaccination and major cardiovascular and haematological adverse events in Abu Dhabi: retrospective cohort study

Marco A. F. Pimentel, Maaz Shaikh, Muna Al Safi, Yousuf Naqvi, Shadab KhanNature Communications 2024 · DOI

Abstract

The widespread administration of COVID-19 vaccines has prompted a need to understand their safety profile. This investigation focuses on the safety of inactivated and mRNA-based COVID-19 vaccines, particularly concerning potential cardiovascular and haematological adverse events. A retrospective cohort study was conducted for 1.3 million individuals residing in Abu Dhabi, United Arab Emirates, who received 1.8 million doses of the inactivated BBIBP CorV (by SinoPharm) and mRNA-based BNT162b2 (Pfizer-BioNTech) vaccines between June 1, 2021, and June 30, 2022. The study's primary outcome was to assess the occurrence of selected cardiovascular and haematological events leading to hospitalization or emergency room visits within 21 days post-vaccination. Results showed no significant increase in the incidence rates of these events compared to the subsequent 22 to 42 days following vaccination. Analysis revealed no elevated risk for adverse outcomes following first (IRR 1·03; 95% CI 0·82-1·31), second (IRR 0·92; 95% CI 0·72-1·16) and third (IRR 0·82; 95% CI 0·66-1·00) doses of either vaccine. This study found no substantial link between receiving either mRNA and inactivated COVID-19 vaccines and a higher likelihood of cardiovascular or haematological events within 21 days after vaccination.

Introduction

While the efficacy of COVID-19 vaccines is well-documented, public concern has persisted regarding rare but serious cardiovascular and haematological (CVDH) adverse events, such as myocarditis, strokes, or blood clots. Most existing safety data focuses on Western populations and mRNA or viral-vector platforms. Consequently, a significant data gap exists regarding inactivated vaccines, such as Sinopharm’s BBIBP-CorV, which served as the cornerstone of vaccination campaigns in the Middle East, North Africa (MENA), and China.

This study addresses these gaps by analyzing the safety profiles of both mRNA (Pfizer-BioNTech) and inactivated vaccines within the same highly diverse, multi-ethnic population in Abu Dhabi. By tracking 1.3 million individuals, researchers aimed to provide a comprehensive "real-world" assessment of vaccine safety across multiple doses.

Methods and Study Population

The researchers employed a retrospective cohort study design using a modified rapid cycle analysis. To minimize biases related to healthcare access or pandemic-related behavioral changes, they compared the "risk interval" (1–21 days post-vaccination) to a "comparison interval" (22–42 days post-vaccination) within the same vaccinated population. Poisson regression was used to calculate Adjusted Incidence Rate Ratios (IRRs), accounting for variables such as age, gender, nationality, and the timing of administration.

The study utilized the Malaffi database, Abu Dhabi’s centralized Health Information Exchange. The cohort included 1,312,505 vaccinated individuals aged 12 and older, representing a wide array of WHO regions, including South-East Asia and the Eastern Mediterranean.

Demographic characteristics of the study cohort across different vaccine types and doses.

Key Results

The quantitative results indicated no elevated risk for the primary composite outcome, which included acute myocardial infarction, stroke, pulmonary embolism, and myocarditis. The safety profile of the traditional inactivated vaccine (Sinopharm) was found to be comparable to the newer mRNA technology (Pfizer).

Key findings include:

  • Overall Risk Stability: The IRRs for the primary outcome were 1.03 for the first dose, 0.92 for the second, and 0.82 for the third, indicating that the risk remained at or below baseline levels.
  • Booster Safety: Data from the third dose suggested no cumulative triggering effect; in fact, the risk of adverse events appeared lower after the booster compared to the initial series.
  • Specific Event Analysis: No significant associations were found for major events like acute myocardial infarction or non-haemorrhagic stroke across the 21-day window. A minor, transient signal (IRR 1.47) was noted within the first 7 days following the second dose of the Pfizer vaccine, but this did not persist across the full 21-day risk period.
Incidence Rate Ratios (IRRs) for primary outcomes following vaccination doses.

Discussion and Conclusion

This large-scale study provides reassuring evidence regarding the short-term safety of both mRNA and inactivated COVID-19 vaccines in a diverse population. The use of concurrent comparators helped mitigate the "healthy vaccinee" effect, ensuring that the findings reflect actual safety profiles rather than behavioral biases.

However, the study has limitations. It relied on ICD-10 diagnostic codes from hospital records, potentially missing mild adverse events that did not require emergency or inpatient care. Additionally, while the sample size was massive, some extremely rare events lacked the statistical power for definitive sub-type conclusions. Finally, the 21-day window focuses on acute reactions and does not address long-term cardiovascular outcomes.

In conclusion, the findings reinforce the safety of the vaccination campaign in the MENA region, supporting the continued use of both vaccine platforms as safe tools for public health.

Summary updated

Abstract

The widespread administration of COVID-19 vaccines has prompted a need to understand their safety profile. This investigation focuses on the safety of inactivated and mRNA-based COVID-19 vaccines, particularly concerning potential cardiovascular and haematological adverse events. A retrospective cohort study was conducted for 1.3 million individuals residing in Abu Dhabi, United Arab Emirates, who received 1.8 million doses of the inactivated BBIBP CorV (by SinoPharm) and mRNA-based BNT162b2 (Pfizer-BioNTech) vaccines between June 1, 2021, and June 30, 2022. The study's primary outcome was to assess the occurrence of selected cardiovascular and haematological events leading to hospitalization or emergency room visits within 21 days post-vaccination. Results showed no significant increase in the incidence rates of these events compared to the subsequent 22 to 42 days following vaccination. Analysis revealed no elevated risk for adverse outcomes following first (IRR 1·03; 95% CI 0·82-1·31), second (IRR 0·92; 95% CI 0·72-1·16) and third (IRR 0·82; 95% CI 0·66-1·00) doses of either vaccine. This study found no substantial link between receiving either mRNA and inactivated COVID-19 vaccines and a higher likelihood of cardiovascular or haematological events within 21 days after vaccination.
BibTeX
@inproceedings{pimentel2024covid,
  author = {Marco A. F. Pimentel and Maaz Shaikh and Muna Al Safi and Yousuf Naqvi and Shadab Khan},
  title = {{COVID-19 vaccination and major cardiovascular and haematological adverse events in Abu Dhabi: retrospective cohort study}},
  booktitle = {Nature Communications},
  year = {2024},
  doi = {10.1038/s41467-024-49744-6},
}
Figure